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Abstract Since the 1980s the genetic cause of many
hereditary tumor syndromes has been elucidated. As a con-
sequence, carriers of a deleterious mutation in these genes
may opt for prenatal diagnoses (PND).We studied the uptake
of prenatal diagnosis for five hereditary cancer syndromes in
the Netherlands. Uptake for retinoblastoma (Rb) was com-
pared with uptake for Von Hippel–Lindau disease (VHL),
Li–Fraumeni syndrome (LFS), familial adenomatous poly-
posis (FAP), and hereditary breast ovarian cancer (HBOC).
A questionnaire was completed by all nine DNA-diagnostic
laboratories assessing the number of independent mutation-
positive families identified from the start of diagnostic test-
ing until May 2013, and the number of PNDs performed for
these syndromes within these families. Of 187 families with
a knownRb-genemutation, 22 had performed PND (11.8%),
this was significantly higher than uptake for FAP (1.6%) and
HBOC (\0.2%). For VHL (6.5%) and LFS (4.9%) the dif-
ference was not statistically significant. PND for Rb started
3 years after introduction of diagnostic DNA testing and
remained stable over the years. For the other cancer syn-
dromes PND started 10–15 years after the introduction and
uptake for PND showed an increase after 2009.We conclude
that uptake of PND for Rb was significantly higher than for
FAP and HBOC, but not different from VHL and LFS. Early
onset, high penetrance, lack of preventive surgery and per-
ceived burden of disease may explain these differences.
Keywords Retinoblastoma  Prenatal diagnosis  Von
Hippel–Lindau disease  Li–Fraumeni syndrome  Familial
adenomatous polyposis  Hereditary breast ovarian cancer
Introduction
Approximately 5% of all cancers are caused by a genetic
predisposition, with the mode of inheritance being mainly
autosomal dominant. In the past 30 years the genetic cause
of many hereditary cancer syndromes has been unravelled.
Knowledge of the genetic predisposition can aid early
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diagnosis and management of cancer for affected mutation
carriers. For unaffected family members, presymptomatic
DNA diagnosis of the disease-associated mutation may
enable informed choices about cancer screening or risk
reduction strategies, including preventive surgery. Cancer
genetic testing, however, can also affect reproductive
decisions of mutation carriers [1–5]. Reproductive options
for couples at risk of having a child with a cancer risk
predisposition may be: refraining from having children or
accepting the risk, adoption or gamete donation. Other
options may include preimplantation genetic diagnosis
(PGD) (i.e. in vitro fertilization, with genetic testing of 1 or
2 cells of the embryo and transfer of unaffected embryos to
the uterus) and prenatal diagnostic testing for the delete-
rious cancer gene mutation with the option to terminate the
pregnancy in the case of a carrier foetus. Prenatal diagnosis
(PND) and PGD for hereditary cancer syndromes were
described as early as 1988 and 1998, respectively [6, 7].
Legal aspects of these two techniques, and thus availabil-
ity, differ across countries; e.g. in some countries PND
followed by abortion is not allowed, whereas in other
countries PGD is prohibited [8, 9]. Access to PND and/or
PGD is also limited in some countries because they are not
covered by health insurances [9]. Both in society and in
medical literature, PND and PGD for hereditary cancer
syndromes have led to ethical, social and legal discussions
[10–15]. Issues under debate are that many cancer-predis-
posing mutations have incomplete penetrance and that the
onset of disease often does not occur until early adulthood.
Furthermore, some argue that through the early detection of
cancer or preventive surgery, the disease may be managed
without a substantial effect on quality of life [15]. Argu-
ments put forward in favour of offering PND and PGD are
that preventive surgery may have a large impact on psy-
chosocial well-being [16] and that families with hereditary
cancer syndromes are burdened by their increased risk and
deserve the same choices as families with other high-risk
hereditary diseases [12, 17].
PND with the intention to terminate the pregnancy of an
affected child is likely to reflect the perceived burden of the
disease, i.e. future parents will only consider PND when
they perceive the disease to be severe and wish to prevent
their child from suffering [14]. In the Netherlands, PND for
most hereditary cancers is offered as a reproductive option
after extensive and careful consultation of the future par-
ents with the clinical geneticist, a psychosocial worker and
the gynaecologist [18, 19]. In several countries, PND for
cancer syndromes has been performed, as listed in a review
from 2006 [1]. However, most of the studies from this
review are case descriptions, and papers on consecutive
series on the uptake of PND for cancer are sparse.
We previously reported on reproductive decisions of
couples at risk of having a child with retinoblastoma (Rb),
a rare type of eye cancer in early childhood [3, 4]. Several
couples who participated in these studies reported that they
had chosen PND to prevent the birth of an affected child
with Rb. The present study was conducted to determine
how many families have used PND as a reproductive
option for Rb since DNA diagnosis for Rb became avail-
able in the Netherlands in 1990. To put these data into
perspective, we compared the use of PND for Rb to the
uptake of PND for four other cancer syndromes with
autosomal dominant inheritance.
Methods
Design
Comprehensive retrospective study in all (nine) academic
diagnostic DNA laboratories within the Netherlands.
Choice of hereditary cancer syndromes
A comparison was made between Rb and four autosomal
dominantly inherited cancer syndromes, i.e. Von Hippel–
Lindau disease (VHL), Li–Fraumeni syndrome (LFS),
familial adenomatous polyposis (FAP) and BRCA1- and
BRCA2-related hereditary breast ovarian cancer (HBOC).
These syndromes were selected as examples of cancer
syndromes that may have cancer onset in early childhood
(VHL, LFS), adolescence (FAP) or in adult life only
(HBOC). Cancer syndromes with\40 families registered
at the nine diagnostic DNA laboratories within the
Netherlands were not considered due to presumed lack of
power in the comparisons. Information on the different
cancer syndromes is provided in Box 1.
Genetic counselling and DNA testing
In the Netherlands, costs for genetic counselling and DNA
testing are covered within the national health service, and
exclusively carried out by the DNA laboratories of the
departments of clinical genetics of the university hospitals.
All patients or their parents had at least one informative
counselling session at a family cancer clinic with a genetic
counsellor before DNA testing was performed. According
to standard procedures, oral and written information about
the cancer syndrome and the test results were provided.
Reproductive options will have been discussed when the
at-risk counselee was in the reproductive age.
DNA testing of the different cancer syndromes are
apportioned among the nine laboratories; while some genes
are diagnostically tested in nearly all laboratories (e.g.
BRCA1/2), others are tested in only one (e.g. RB1).When a
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pathogenic mutation is detected within a family, DNA
testing of subsequent family members will be performed in
the laboratory in which the initial genetic diagnosis was
made. Therefore the likelihood that family members are
tested in two different laboratories is small. All laboratories
use databases to keep track of family relationships and test
results, including prenatal diagnostic tests.
For this study, a family is defined as all related muta-
tion-positive family members from one family. The age
and gender of the mutation carriers have not been
registered.
The study has been approved by the Medical Ethics
Review Committee of VU University Medical Center
(VUMC) Amsterdam and was conducted in accordance
with the principles of the Helsinki declaration.
Questionnaire
For this retrospective study, molecular geneticists of the
nine DNA laboratories in the Netherlands were asked the
same questions for all five cancer syndromes in May 2013
(end of inclusion):
1. When did DNA diagnostic testing start in your
laboratory?
2. How many mutation-positive families are known in
your laboratory?
3. How many families have opted for PND since DNA
testing became available?
4. What was the date of each PND?
5. How many times has PND been performed per family?
The laboratory was re-contacted when necessary.
National Retinoblastoma Treatment Center
Since 1991, all newly diagnosed Dutch Rb patients are
being treated in the National Retinoblastoma Treatment
Center at the VUMC in Amsterdam. This means that the
majority of patients and their parents visited the clinical
genetics department of VUMC for counselling for Rb. For
this study, we registered which clinical genetics department
in the Netherlands had requested PND for Rb. For the other
hereditary cancer syndromes, there is no central treatment
centre, so (pre-PND) genetic counselling was performed in
all nine clinical genetics departments.
Statistical analysis
To test whether PND was performed more or less often in
Rb families than in families with each of the other hered-
itary cancer syndromes, two-sided Fisher’s exact tests were
used. A Bonferroni multiple testing correction was applied
for the number of tests that were performed (uptake for Rb
was compared with four hereditary cancer syndromes);
p values\0.05/4 = 0.0125 were considered significant.
Results
Table 1 shows the five hereditary cancer syndromes, the
number of mutation-positive families identified in the
Netherlands, the total number of PNDs performed per
cancer syndrome, and the number of couples that per-
formed PND. PND was performed 35 times for Rb by 22
couples from 22 mutation-positive families (11.8% of 187
Box 1 Main characteristics of the hereditary cancer syndromes
Retinoblastoma (Rb) is a pediatric malignant tumor of the embryonic neural retina cells, usually diagnosed in the first few years of life [20]. In
40% of cases Rb is heritable caused by a germline RB1-mutation. Heritable Rb is an autosomal dominant disease with high penetrance: more
than 95% of germline mutation carriers develop Rb. They also have an increased risk of developing other malignancies later in life. Healthy
parents with a child with a de novo RB1 mutation have a 2–3% recurrence risk for their next child, based on possible germline mosaicism.
Von Hippel–Lindau’s disease (VHL) is caused by mutations in the VHL-gene [21]. Its main characteristics are haemangioblastomas of the brain,
retina and spinal cord, renal cysts and renal carcinoma, and phaeochromocytoma. Penetrance is high. Expression varies greatly both within and
between families. Screening starts usually at the age of 5 years in the Netherlands.
Li–Fraumeni syndrome (LFS) is associated with germline mutations in the TP53-gene and is characterized by an increased risk for a variety of
malignancies at young age, sometimes during childhood, including sarcomas, early onset breast cancer, adrenocortical carcinoma, leukemia
and brain tumors [22]. No effective preventive measure currently exists for TP53-mutation carriers, other than awareness and prompt visit to a
physician with unexplained complaints. Recently, annual whole body MRI screening of carriers has started both in the Netherlands and other
countries (e.g. see http://clinicaltrials.gov/ct2/show/NCT01464086), although the effect on survival is currently not known.
Familial adenomatous polyposis (FAP) is caused by mutations in the APC-gene, with virtually complete penetrance: close to 100% of carriers
develop FAP [23]. Carriers develop extensive polyposis of the colon, leading to colon cancer if untreated. Other features include an increased
risk for duodenal polyps and desmoid tumors. Screening for polyps starts from age 10–12 years and preventive colectomy is usually performed
in early adulthood.
Hereditary breast and ovarian cancer (HBOC) is caused by mutations in the BRCA1- or BRCA2-gene. The lifetime risk for women of developing
breast cancer is 40–80% and the cumulative risk of developing ovarian cancer is 11–40% [24]. Breast screening starts at the age of 25 years.
Bilateral salpingo-oophorectomy and bilateral mastectomy are offered as preventive measures.
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mutation-positive families). The percentages of families
opting for PND for the other cancer syndromes ranged from
\0.2% (HBOC) to 6.5% for VHL.
A significant difference in number of PNDs was seen
between Rb and HBOC, and Rb and FAP. No differences
were seen between PNDs for Rb and VHL and LFS.
In 14 out of 22 couples that used PND for Rb, one of the
parents was a carrier of an RB1 mutation and the risk of a
child with Rb was 50%. The other eight families concerned
healthy parents with a child with a de novo RB1 mutation.
The recurrence risk for these couples was 2–3%, based on
possible germline mosaicism. For the other four cancer
syndromes, the risk of an affected child was 50% for all
cases. When confining the comparison analysis to Rb cases
with a 50% risk, a significant difference in use of PND was
still seen between Rb and FAP (p = 0.0011) and Rb and
HBOC (p\ 0.0001).
Number of PNDs per year
In Fig. 1 the number of PNDs for all hereditary cancer
syndromes is plotted per year.
The first PND for Rb was done in 1993 and the last PND
included in the study was done in 2013. In that period there
has been neither a substantial increase nor decrease in the
number of PNDs for Rb per year: the number of PNDs per
year ranged from zero to four, with a mean of 1.5 per year.
The number of PNDs per year for the other cancer syn-
dromes varied between zero and three per syndrome per
year. There was a trend towards more PNDs after 2009:
eight out of a total of 28 PNDs for these cancer syndromes
were performed between 2001 and 2009. The other 20
PNDs were performed between 2009 and 2013.
In 22 out of 35 PNDs for Rb, the pre-PND counselling
and the invasive procedure was done in VUMC, where the
National Retinoblastoma Treatment Center is located and
the remaining thirteen pre-PND counselling and invasive
procedures were conducted elsewhere. Pre-PND coun-
selling and invasive procedures for the other cancer syn-
dromes were performed in all participating hospitals,
except for one: in the National Cancer Institute no invasive
PND procedure is available and those patients were refer-
red to one of the other eight centres.
Time between start of DNA diagnostic testing
and first PND
In Table 2 the year of gene identification, start of DNA
diagnostic testing per cancer syndrome is depicted and
number of years between the start of DNA diagnostic
testing and the year of the first PND. For Rb the first PND
was done 3 years after DNA diagnostic testing had been
introduced in the Netherlands. For the other cancer syn-
dromes the first PND was performed between 10 and
15 years after DNA diagnosis became available.
Analysis comparing uptake for Rb to FAP and HBOC
was done again, while taking into account the year DNA
diagnostic testing became available. Since DNA testing for
FAP has been possible since 1991 and the first PND for Rb
was performed in 1993, the analysis was unchanged for
FAP. For HBOC, uptake of PND for Rb remained signif-
icantly different both for all PNDs (p value\2.2e-16) and
when just comparing PNDs of couples with a 50% risk of a
child with Rb (p value\1.296e-12).
Discussion
In this study, relatively large differences in the use of PND
between cancer-predisposing syndromes were found. A
significantly higher uptake for Rb than for the adult-onset
cancer syndromes HBOC and FAP was seen. Uptake of
Table 1 Cancer syndromes with number of families known in the Netherlands, number of PNDs and comparison with number of PNDs for
retinoblastoma
Cancer
syndrome
Number of families with
a germline mutation
Number
of PNDs
Number of couples that performed PND (percentage of
total number of mutation-positive families)a
Uptake for Rb compared to other
cancer syndrome p value
Rb 187 35 22 (11.8%)
VHL 92 7 6 (6.5%) 0.207
LFS 41 5 2 (4.9%) 0.266
FAP 364 11 6 (1.6%) \0.0001
HBOC [3000 6 6 (\0.2%) \0.0001
Rb retinoblastoma, VHL Von Hippel–Lindau disease, LFS Li–Fraumeni syndrome, FAP familial adenomatous polyposis, HBOC hereditary
breast and ovarian cancer, PND prenatal diagnosis
a Of all couples opting for PND, fifteen performed PND more than once. In 41 out of 42 mutation positive families PND was performed by one
couple per family. In one family with a p53 mutation two different couples performed PND, here taken as one case
Significant p values are in italics
C. J. Dommering et al.
123
PND did not differ significantly between Rb and two other
early onset cancer syndromes VHL and LFS. PND for Rb
started just 3 years after DNA diagnostic testing was
introduced and uptake has been relatively stable over the
years. PND for VHL, LFS, FAP and HBOC started
10–15 years after DNA testing was offered. A trend
towards more PNDs for these syndromes after 2009 was
noted.
The differences in uptake for PND observed in this
study may be explained by several interdependent factors:
differences in age of onset of cancer, disease penetrance,
risk-reducing options and perceived disease burden, as
noted by several authors in papers on PND or PGD for
hereditary cancer [1, 5].
When age of onset is in adulthood, prospective parents
may have the hope for better treatment options in the future
for a carrier child, whereas in the case of childhood-onset the
parents’ concerns will be more immediate. For adult-onset
cancers, cancer diagnosis of an individualmay not have been
made until after family planning was completed. Rb is a
high-penetrance disease of early childhood, and therefore
parents of an affected child with Rb may still be in the
reproductive age at the time of diagnosis of an affected child
and may opt for PND in a subsequent pregnancy. Further-
more, physicians caring for patients with childhood cancer
often havemore intense contactwith the family andwill have
more awareness of a possible impact of childhood cancer on
family planning and be more knowledgeable about repro-
ductive options than physicians caring for adult-onset cancer
patients [31]. Differences in uptakemay also be explained by
the lack of risk-reducing options for the hereditary cancer
syndromes with childhood-onset, apart from screening to
detect cancer at an early stage [32]. For HBOC, mastectomy
and prophylactic salpingo-oophorectomy can reduce cancer
risk substantially, and the same applies to colectomy for
FAP.
Lastly, previous studies on reproduction and hereditary
cancer considered the perceived disease burden by indi-
viduals opting for assisted reproduction a factor of influ-
ence on uptake of PND [5]. For Rb, an extra disease burden
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Fig. 1 Number of PNDs per hereditary cancer syndrome per year. Rb retinoblastoma, VHL Von Hippel–Lindau disease, LFS Li–Fraumeni
syndrome, FAP familial adenomatous polyposis, HBOC hereditary breast and ovarian cancer, PND prenatal diagnosis
Table 2 Genes related to the five hereditary cancer syndromes with year of gene identification, year of start of DNA diagnostic testing in the
Netherlands, year the first prenatal diagnosis (PND) was performed, and the number of years between the start of testing and the first PND
Cancer syndrome Related gene Year of gene
identification
Start DNA testing
in the Netherlands
First PND Number of years between
start DNA testing and first
PND
Rb RB1 1986 [25] 1990 1993 3
VHL VHL 1993 [26] 1994 2006 12
LFS TP53 1990 [27] 1995 2010 15
FAP APC 1991 [28] 1991 2001 10
HBOC BRCA1/BRCA2 1994 [29]/1995 [30] 1995 2005 10
Rb retinoblastoma, VHL Von Hippel–Lindau disease, LFS Li–Fraumeni syndrome, FAP familial adenomatous polyposis, HBOC hereditary
breast and ovarian cancer, PND prenatal diagnosis
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follows from the intensive ophthalmological screening,
which is done under anaesthesia in the first few years of
life. Also, patients with heritable retinoblastoma have an
increased risk for both a pineoblastoma (also referred to as
trilateral retinoblastoma) and second tumours later in life
and many have considerable late effects of treatment, e.g.
an impaired vision or hearing loss. Perceived disease bur-
den is not always related to a personal history of cancer,
but can be shaped by many aspects, like caring for a family
member with cancer [1, 5]. In our study of reproductive
behaviour of individuals at risk of a child with Rb, the most
important factor of influence on reproductive behaviour
was perceived risk, not objective risk [4]. Both perceived
disease burden and perceived risk may therefore be part of
the reason eight parents with a child with a de novo RB1
mutation opted for PND, in spite of a recurrence risk of
\3%.
One of the possible reasons PND uptake for Rb may
differ from uptake for FAP and HBOC could be that
diagnostic DNA testing of Rb started earlier than for FAP
and HBOC. Therefore analysis comparing uptake for Rb to
FAP and HBOC was done again, while taking into account
the year DNA diagnostic testing became available. This
analysis, however, did still show a significant difference
between uptake for Rb and uptake for FAP and HBOC.
Observed higher uptake for Rb may be a reflection of
differences in counselling between our clinical genetics
department (with the highest number of counselees for Rb)
and the other eight clinical genetics departments in the
Netherlands. However, 13 PNDs and pre-PND counselling
for Rb were performed elsewhere. Since there is a close
collaboration between the nine clinical genetics depart-
ments in the Netherlands, policy towards counselling and
PND is much the same.
PND for hereditary cancer has been reported in other
countries, although in limited numbers, making it difficult
to compare these data to our findings [1]. One paper on the
clinical perspective on ethical arguments around PND and
PGD for later-onset cancer syndromes from the Regional
Genetics Service in Manchester mentioned one couple out
of 110 families with FAP known in their centre that had
undergone PND, and none from 356 HBOC families [14].
In Canada, PND for Rb is done to enhance early man-
agement of RB1 carrier infants and not with the option to
terminate the pregnancy [33]. In the case of an affected
child, premature delivery at 36 weeks’ gestation is rec-
ommended to be able to treat as early as possible.
One of the limitations of this study is that the number of
mutation carriers in the reproductive age in each family was
not known. However, since a relatively large number of
families were included, we believe that our data on the
uptake of PND in the cancer syndromes are by and large
reliable. A trend towards increasing uptake of PND for
hereditary cancers other than Rb after 2009 was observed. In
2008, PGD for hereditary cancer was temporarily restricted
by the Dutch Minister of Health because of an ethical debate
on PGD for diseases with a penetrance of\100%, such as
HBOC [34]. Public debate in the media about hereditary
cancer and reproduction during those years may have alerted
at-risk couples to the option of both PGD and PND. Future
research will have to determine whether the observed
increasing trend of PND uptake over the past 5 years for
VHL, LFS, FAP and HBOC will continue.
In conclusion, PND for Rb started many years before it
was used for the other hereditary cancer syndromes. PND
has been done significantly more often for Rb than for FAP
and HBOC. Uptake of PND was not significantly different
between Rb and VHL, and Rb and LFS. Early onset, high
penetrance, lack of preventive surgery and perceived bur-
den of disease may explain these differences. Knowledge
regarding the underlying motives of couples that have
opted for PND as a reproductive option is useful to
improve care for families with a genetic predisposition for
cancer.
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